At present, the voice has a strong product portfolio of more than 50 drugs, focusing on the treatment of tumors, cardiovascular and cerebrovascular diseases, infections and other diseases. Including "Zailin", the market-leading generic amoxicillin antibiotic enjoys a separate pricing policy and has been recognized as "China Famous Trademark" by the State Administration for Industry and Commerce; The first generic anti-stroke drug in China and the second generic anti-stroke drug in the world, which entered the market in 2004, is the first new free radical scavenger with clear action mechanism; Endo, the first innovative anti-cancer drug of recombinant human endostatin approved for marketing in China, has patents in China and the United States, and won the 10th China Patent Gold Award and the second prize of the National Technological Invention Award in 2008. And three other brand drugs with annual sales exceeding 70 million or over 100 million: Yingtaiqing, bigi and Anqi; Among them, Yingtaiqing was awarded the title of "China Famous Trademark" in February 2008. In 2008, after five years of research and development, biapenem, an anti-infective drug for injection, was first marketed in China, providing a new treatment option for patients with moderate and severe infections in China. Simcere has an extensive distribution network and professional marketing team in China, with more than 800 salespeople and more than 65,438+000 strategic partners, 80% of whom have medical degrees. In China, Xiansheng has more than 1500 dealers. Our products are sold to more than 4,000 hospitals and 70,000 pharmacies in China. Every year, there are thousands of academic conferences sponsored, undertaken and co-organized by simcere, and hundreds of academic materials and papers are collated, so tens of thousands of doctors learn, communicate and improve better. In 2004, simcere Research Institute was established, which has a number of technical platforms for the research of chemical drugs and biological drugs. At present, 89 China invention patents have been applied for or obtained, and 10 pioneering and exclusive varieties have been successfully developed and listed. The project of "New Medicine Hot Intestine Tablets" won the second prize of National Science and Technology Progress Award. In 2003, with the approval of the Ministry of Personnel, the postdoctoral research mobile station was established, and 1 1 postdoctoral fellows entered the station one after another. On June 5438+ 10, 2006, Xiansheng Technology and Tsinghua University established the "Joint Laboratory of Innovative Drugs". At the same time, we cooperated with Nanjing University, China Pharmaceutical University, Shanghai Institute of Pharmacology of China Academy of Sciences, Shanghai Institute of Organic Chemistry of Chinese Academy of Sciences and Edwin Laboratory Co., Ltd. At the end of 2006, the modern R&D center of Xiansheng Pharmaceutical Research Institute, which covers an area of more than 5,000 square meters, was officially opened, and more new drugs are being bred.
The research and development of voice new drugs is market-oriented, focusing on innovative drugs with broad market potential or brand generic drugs developed first in China market. We focus our research and development work on the treatment of diseases with high morbidity or mortality and more effective drug demand, such as cancer, stroke, osteoporosis and infectious diseases. In recent years, the voice launched a series of brand generic drugs or innovative drugs, such as Renzhong Fuan, Jiebaishu and Anxin, which took the lead in entering the market, and filled many gaps in China. At present, simcere has more than 65,438+00 research projects at different stages of research and development. 1995 March-Jiangsu Chen Gong Pharmaceutical Co., Ltd., the predecessor of the voice, was established. Create a "total distribution" model for pharmaceutical marketing enterprises in China.
200 1- Holding Hainan Haifu Pharmaceutical Co., Ltd. (later renamed as Voice Co., Ltd.) to establish pharmaceutical production capacity.
2003-Acquired Nanjing Dongyuan Pharmaceutical Co., Ltd. (later renamed Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd.) to further strengthen the product portfolio and production capacity.
2004-Jiangsu Xiansheng Pharmaceutical Research Co., Ltd. was established, and a comprehensive research and development platform was established.
September 2005-Hony Capital, a subsidiary of Lenovo Group, completed its equity investment in simcere.
April 2007-simcere successfully landed on the new york Stock Exchange with the stock code SCR, becoming the first biochemical drugs company in China to be listed on the NYSE. Break through the old model of drug marketing;
-1995, creating a "general distribution" model for pharmaceutical marketing enterprises in China.
—— The first company in China to provide all-round services such as product packaging design, advertising planning and terminal promotion for pharmaceutical manufacturers.
-The annual sales of the first "exclusive distribution" drug in China exceeded 300 million yuan.
Abandoning the old drug sales model, taking the lead in adopting the new "total distribution" model and achieving impressive results, which laid the foundation for the development of the voice and completed the original accumulation of the enterprise. Simcere successively acquired and controlled:
Jiangsu Hanhe Pharmaceutical Co., Ltd.
-Hainan Haifu Pharmaceutical Co., Ltd.
-Shanghai Haciyi Pharmaceutical Co., Ltd.
—— Nanjing Dongyuan Pharmaceutical Co., Ltd.
—— Yantai Maidejin Bioengineering Co., Ltd.
—— Jilin Boda Pharmaceutical Co., Ltd.
Nanjing Dongjie Pharmaceutical Co., Ltd.
Wuhu renzhong pharmacy co., ltd
Focusing on the M&A expansion of pharmaceutical production enterprises, simcere has surpassed the single business scope of pharmaceutical marketing, and its independent production capacity has ensured the independence of enterprises and greatly enhanced their ability to resist risks. On the basis of integrating R&D assets and teams of Jiangsu simcere New Drug Research Center, Hainan Chemical Medicine Engineering Technology Research Center and Jiangsu Pharmaceutical Industry Research Institute Co., Ltd., simcere established Jiangsu simcere Research Co., Ltd. in 2004.
From June 2003 to February 2003, with the approval of the Ministry of Personnel, Xiansheng Technology established a postdoctoral research center, and in 2006, it established a "Joint Laboratory for Innovative Drugs" with Tsinghua University. At the end of 2006, a 5,000-square-meter drug research and development base was put into use at the eastern foot of Nanjing Zijin Mountain.
Establishing a drug research and development team and independent research and development capabilities constitute the core competitiveness of Xiansheng. Occupy the commanding heights of technology and constantly introduce new products with advantages, which ensures the sustainable development of Xiansheng and injects eternal vitality into the enterprise. 20 1 1 White House Station, New Jersey, USA, 201/news-Merck (NYSE:MRK, commonly known as Merck outside the United States and Canada) and China's simcere (NYSE:SCR) officially announced today.
The two partners announced the news at the signing ceremony held by Merck Research Institute in Ravi, New Jersey, USA. Chairman of the board of directors of Merck Co., Ltd. Ke Jiarui; History of President of Merck Global Human Health Department; Feng Naxi, President of Merck East China District; Ren Jinsheng, Chairman and CEO of Voice Group; And Dr. Zhang, President of Xiansheng Technology, attended the signing ceremony.
Member the Political Bureau of the Communist Party of China (CPC) Central Committee, Secretary jiangsu provincial party committee and Director of the Standing Committee of Jiangsu Provincial People's Congress Luo Zhijun attended the signing ceremony.
This novel and creative way of cooperation will bring together the rich R&D and sales experience and resources of a multinational pharmaceutical company and a leading pharmaceutical company in China, so as to achieve the goal of establishing a strategic partnership between the two sides. The cooperation will include product research and development, registration, manufacturing and sales of both parties. In addition, in the initial stage of cooperation, we will focus on leading brand drugs in the field of cardiovascular and metabolic diseases.
According to the cooperation agreement between the two companies, the two companies will provide the joint venture company with their selected brands and generic drug combinations in the field of cardiovascular diseases, including Merck/Merck &; Reg (simvastatin), Kosuya &; Reg (losartan) and renitec &；; Reg from simcere (enalapril) and Cinta (amlodipine besylate) and Sufutan (rosuvastatin). At the same time, the two sides will actively cooperate to improve the accessibility of sitagliptin for diabetic patients in China. Sigliptin is an innovative DPP-4 inhibitor, which is used to treat type 2 diabetes. In China, the obvious public health threat caused by type 2 diabetes is increasing. "Merck is honored to cooperate with the voice. Xiansheng is a leading pharmaceutical company in China. Merck and Xiansheng have the same mission, which is to promote the development of medical and health undertakings in China. " Shi said, "At the same time, cooperation is also an important step for Merck to expand its business strategy in China, which coincides with the goal of the China government to improve the accessibility of quality drugs."
"Today's cooperation is another important milestone in Saisen's unremitting pursuit of improving patients' quality of life by providing innovative drugs. Ren Jinsheng said, "The purpose of this innovative cooperation is to meet the enormous challenges of China's medical system and meet the needs of China patients and other medical stakeholders. "
"The cooperation between Xiansheng and Merck is not only of strategic significance to both companies, but also a landmark event in the biopharmaceutical industry in Jiangsu Province." Luo Zhijun, secretary of jiangsu provincial party committee and director of the Standing Committee of Jiangsu Provincial People's Congress, pointed out, "The biopharmaceutical industry is a strategic emerging industry that Jiangsu Province focuses on. The cooperation between Merck and Xiansheng will inject fresh impetus into the development of the whole industry and help Jiangsu provide more high-quality drugs for China and the world. "
The establishment of a joint venture will depend on the finalization of the terms of cooperation between the two parties.
The vision of Vonaxi, president of Merck China, three months ago, instantly became a reality. On July 22nd, Merck of the United States, the second largest pharmaceutical company in the world (called Merck outside the United States and Canada), signed a framework cooperation agreement with China Synthetic Apex Group and decided to establish a joint venture company in China. The two sides took out their selected brands and generic drug combinations and handed them over to the joint venture company for operation, thus achieving a major breakthrough in the cardiovascular and diabetes drug market. According to its three-year strategic plan, Merck will carry out a series of cooperation, acquisition and merger measures to improve its original marketing channels.
In September 2009, Feng Naxi, who just took over the China market for nine months, said in an interview with the media that for R&D company, the development speed of China market is faster than anywhere else. Among the most valuable markets in the world, China will become the third in three years and the largest vaccine market in the world by 2020.
Although the market in China is highly appraised, the development pace of Merck, which has been in China for 20 years, is not remarkable, which is due to its unsatisfactory channel promotion and high drug price.
In order to change this situation, Merck took the initiative to reduce the price of drugs for cardiovascular diseases to 20 10 by 52%, becoming the first foreign-funded original drug to enter the national list of essential drugs. Feng Naxi admits that this will greatly reduce profits, but in exchange for more coverage of medical institutions, especially grassroots community health centers. The planned joint venture will focus on generic drugs with relatively low prices, which will undoubtedly help Merck achieve wider coverage.
The courseware of Merck 20 10 shows that its business focus is to expand the use of products in primary medical institutions, especially for chronic diseases that need long-term use; Ensure the market access of products in every province and city, continue to speed up market development and multi-channel market education, so that products can be effectively distributed to the vast market; At the same time, explore the establishment of business partner cooperation mode to improve product coverage.
Feng Naxi said that in the next three years, Merck will continue to deepen the China market and expand its new business capabilities through three channels: First, strengthen its own business; Second, look for strategic partners; Third, mergers and acquisitions.
The cooperation with simcere is Merck's second development plan while strengthening its own business.
According to the data, simcere has a sales team of more than 800 people, more than 65,438+000 strategic partners and more than 65,438+0,500 distributors in China, and its products are marketed to more than 4,000 hospitals and 70,000 pharmacies. And these are exactly what Merck lacks.
Feng Naxi's development strategy for the next three years also includes the arrangement based on the unbalanced development between the eastern and western parts of China. "We have established ten regions according to the urban clusters in various regions of China, and established the regional general manager responsibility system respectively. It should be said that we are the first multinational pharmaceutical company to deploy nationwide. "
I'm afraid Feng Naxi can't just expect a simcere to make these ten regions play the expected role. In the future market breakthrough, he will make more use of M&A to achieve rapid scale expansion, so as to grasp the huge business opportunities created by China medical reform.
"China wants to establish a perfect medical and health security system, which is not available in other countries in the world. Medical reform in developing countries is usually to establish a preliminary medical system, while China has begun to establish a medical system that basically covers the whole country, especially the national essential drug system, with the aim of solving the accessibility of drugs, improving the coverage of medical insurance, and narrowing the differences in medical environment between the east and the west. " Feng Naxi said.
Like Merck, many multinational pharmaceutical giants have taken a fancy to the business opportunities of medical reform in China. It is conceivable that the competition will be more intense in the future. Whether Merck can change the long-standing tepid situation depends on how brave it is to break through itself.
Merck is not the first multinational pharmaceutical company to establish a joint venture with a domestic pharmaceutical company. In June this year, Pfizer, the world's largest pharmaceutical company, signed a letter of intent with Haizheng Pharmaceutical Co., Ltd., and the two sides will jointly set up a joint venture company to realize the wider commercialization of related drugs through a global marketing platform. Before Pfizer, Novartis, another pharmaceutical giant, also announced the completion of the joint venture with China vaccine company Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
Why do domestic pharmaceutical companies attract multinational pharmaceutical giants to establish joint ventures? Dai Haosen, a medical expert, told reporters that the most important purpose of cooperation between multinational pharmaceutical companies and China companies is to occupy a larger share in the China market. Because multinational pharmaceutical companies are in a leading position in technology and products, they are not as good as domestic enterprises in domestic market expansion and understanding of China policies. Moreover, cooperating with domestic enterprises in production and sales can reduce the cost of multinational pharmaceutical companies, and for domestic enterprises, they can also learn from foreign advanced technology and management experience.
At the same time, an industry insider said that in the past, if multinational pharmaceutical companies wanted to continue to grow and develop, most of them would adopt mergers and acquisitions, but there were not many good companies worth acquiring in the market, and they might not be able to acquire them. Therefore, large multinational pharmaceutical companies began to gradually replace "acquisition" with "investment".
The cooperation between Merck (called "Merck" outside the United States and Canada) and Xiansheng, which has received much attention before, is rapidly entering the practical level.
"We hope to start cooperative sales on September 1 day to show our complementarity. Quick results are also an innovation of our cooperation. " Ren Jinsheng, Chairman and CEO of the Board of Directors of Voice Group, said excitedly at the press conference of Merck and Voice in August 16. At this meeting, the two sides revealed the contents of cooperation and more details of establishing a joint venture in China. As for the financial details of the joint venture company, which are widely concerned by the outside world, both parties said that it is inconvenient to disclose them. "Since both companies are listed in the United States, the relevant figures will be published in the bulletins or financial reports of the two companies." Feng Naxi, senior vice president of Merck and president of Merck China, stressed, "I can assure you that our investment amount is absolutely enough to achieve our grand goal."
According to reports, this strategic cooperation will be developed in stages: in the short term, the two sides will set up a joint venture company in Shanghai on 20 13, and the joint venture company will jointly promote and sell the best-selling products of both sides; In the long run, Merck and Voice will complete the comprehensive integration of the joint venture company in 2020, strengthen their research and development capabilities in the fields of cardiovascular and metabolic diseases, and build a pharmaceutical factory in Nanjing. According to the cooperation agreement, the two sides will integrate resources and cooperate in product research and development, registration, manufacturing and sales. In the early stage, the focus was on the cooperative development of leading brand drugs and generic drugs in the field of cardiovascular and metabolic diseases, and the international market was not involved for the time being.
After more than nine months of negotiations, more than 65,438+0,000 pages of documents far exceeded Ren Jinsheng's expectations, but also convinced him that through this cooperation, Merck and the voice will enjoy their respective advantages in the market, channels and R&D fields.
According to the cooperation agreement, the two companies will provide the joint venture company with their selected brands and generic drug combinations in the field of cardiovascular diseases, including Merck's Shujiangzhi (simvastatin), Kosova (losartan) and Ranitidine (enalapril), Xintai (amlodipine besylate) and Sufutan (rosuvastatin). At the same time, the two sides will also make efforts in the field of diabetes to improve the accessibility of sitagliptin for diabetic patients in China. Sigliptin is an innovative DPP-4 inhibitor, which is used to treat type 2 diabetes.
"In addition, we must cooperate to develop drugs suitable for the China market, including market-oriented improvement of existing drugs. I think this is all within the scope of our cooperation. Therefore, on the basis of abundant products and resources, we need to pay more attention to the understanding of the market, so as to help more excellent drugs achieve wide coverage in the China market. This is the basic starting point of our cooperation. " Ren Jinsheng said. Previously, Merck has always stressed that in the next three years, Merck will continue to deepen the China market and expand new business capabilities through three channels: one is to strengthen its own business, the other is to find strategic partners, and the third is mergers and acquisitions. "This cooperation with simcere is a typical embodiment of the second method. Through this cooperation, we will learn from leading local companies and further penetrate into the local market. " Feng Naxi said.
For Xiansheng, before reaching a cooperation with Merck, we have been exploring deep-seated opportunities for international cooperation. For example, we have cooperated with Advenchen Company, OSI Biopharmaceutical Company and BMS Company.
In fact, under the general trend of internationalization of China's pharmaceutical industry, the cooperation between local enterprises and multinational companies has emerged in an endless stream, which is considered by the industry as a new era of joint venture.
Although the cooperation between local companies and multinational companies can combine the advantages of both sides and has great development potential, so far, there are not many successful cases. This also makes the outside world worry about the cooperation between Merck and Xiansheng.
In this regard, Zhang, president of the voice, said: "There are many reasons, and the most important point is that it is difficult to find a truly like-minded partner. Therefore, I think there are some reasons why our negotiations have taken so long. " In his view, the current cooperation between the two sides is all-round and truly innovative, and the platform built has great potential, but the key is whether it can truly reflect the value at a breakthrough point. "If it can be reflected, then this thing is like a snowball, rolling bigger and bigger, to an extent that we can't imagine."
In order to further strengthen disease classification management, evaluate the quality of diagnosis and treatment of rheumatism, and improve the level of diagnosis and treatment of rheumatism in China, the National Data Center for Diagnosis and Treatment of Rheumatism (CRIS Center for short) was established in Beijing on 201165438+1October 27th. Leaders of the Department of Medical Management of the Ministry of Health, members of the Rheumatology Branch of the Chinese Medical Association, and 42 professional rheumatologists from all over the country attended the kick-off meeting of CRIS Center. At the kick-off meeting of CRIS Center, Simcere held a satellite meeting of Aidixin, a new national rheumatoid drug. The satellite conference was presided over by Professor Zeng Xiaofeng, Chairman-designate of China Rheumatology Branch. At the meeting, Professor Li Xiaofeng from the Second Affiliated Hospital of Shanxi Medical University made a full discussion on the time to market, product information, advantages, etc. Through this satellite meeting, experts from the Department of Rheumatology of the National 142 Key Hospital clearly and in detail learned the news of the upcoming listing of Adelson and the information of its core products. At the same time, simcere took this opportunity to establish a good communication and cooperation mechanism with rheumatologists all over the country, which laid a very important foundation for Aidexin, which will be listed in the whole country.
Edexin is the first ilamod preparation listed in the world, and it is also a brand-new structural type of DMARDS. Its main indication is active rheumatoid arthritis, which can significantly improve the disease symptoms and inflammatory indicators of patients with rheumatoid arthritis and relieve their pain. On August 24th, 20 1 1, the voice announced that Edxin (Erasmus tablets) had been officially awarded the national first-class new drug certificate and drug registration approval issued by SFDA of China. Edson will be listed nationwide on June 20 12. 1995, Zailin was born.
1June, 1996, signed an exclusive distribution agreement with Yaoda Pharmaceutical Factory.
From 65438 to 0996, we built a Hope Primary School in Lianshui, Huai 'an.
1September, 1997, the general distribution contract of Kechuanning was signed.
1998, just like the once-in-a-century flood, we donated 1 10,000 yuan of medicine.
1999, we completed the transformation from minister to pioneer.
In 2003, the company signed a cooperation agreement with Dongyuan Pharmaceutical.
In 2003, we established the voice group. In 2003, we also donated the second Hope Primary School in Hainan.
In 2003, the foundation stone was laid for the new site of Xiansheng Group and Institute of Medicine.
In 2003, we donated 654.38 million yuan in medical assistance.
In 2004, the first sound cup excellent hospital dean commendation meeting.
In 2004, the "International Forum on Innovative Drugs" sponsored by the Institute of Pharmaceutical Research won the well-known trademark of China and began to use new packaging.
In 2004, there will be the first domestic listing.
In 2005, we established the Hospital Management Outstanding Contribution Award Fund in China Hospital Management Institute.
In 2005, we introduced Lenovo Hongyi Company.
At the end of 2005, Beach introduced new packaging and began to publish advertisements.
In early 2006, we established a joint laboratory with Tsinghua University.
In 2006, the Pharmaceutical Affairs Management Committee of China Hospital Association was held in Hefei.
In 2007, we held an academician forum on innovative drug development strategy.
In 2006, we acquired Yantai Metro by lightning.
Subsequently, we quickly introduced Endor to the market, and Endor's listing attracted the attention of many well-known media at home and abroad.
In the four clean-ups in 2007, everyone was heart to heart.
On April 20, 2007, simcere landed on the New York Stock Exchange, and simcere announced that it would invest $52 million raised by IPO in new drug research and development.
In September 2007, Xiansheng acquired 5 1% equity of Jilin Boda.
In June 2007, Xiansheng completed the acquisition of Dongjie Pharmaceutical and its anti-tumor chemotherapy drug Jiebaishu.
June 5438+October 2008 10, Endor's invention patent won the 10th China Patent Gold Award.
In April 2008, Xiansheng acquired 70% equity of Wuhu Renzhong Pharmaceutical.
In 2009, we participated in Shanghai Jinsai and held a promotion meeting in Jiangsu.
Enterprises to further expand their participation in the field of biopharmaceuticals. We have successfully brought Thaksin, an antihypertensive drug, to the market, which indicates that simcere has entered the field of cardiovascular treatment on a large scale.
Our anti-inflammatory and analgesic brand Yingtaiqing has become the promotion partner of NBA in China.
In 2009, Ren Jinsheng, the second phase project of Xiansheng Pharmaceutical Research Institute with a total investment of nearly 300 million yuan, officially broke ground in Nanjing.
Ren Jinsheng, founder of simcere, is currently the chairman and CEO of simcere. Ren Jinsheng 1982 graduated from Nanjing University of Chinese Medicine. 1982~ 1992 worked for qidong gaitianli pharmaceutical co., ltd, and successively served as technician and deputy general manager; 1992~ 1995 as department manager of Jiangsu pharmaceutical industry company; Simcere was founded in March 1995; In 2003, he obtained a master's degree in economics from Macquarie University in Australia. He is currently a visiting professor at China Pharmaceutical University, a visiting professor at Nanjing University of Chinese Medicine and an adjunct professor at Northwest University in China.
Liu Hongquan
Liu Hongquan, executive director and CEO of the voice board of directors, has 30 years of management experience in the medical field; Bachelor degree from Shanxi University of Finance and Economics, EMBA degree from China Europe International Business School. From 2000 to 20 12, Mr. Liu Hongquan served as the director and general manager of Fei Sen Juskabi Huarui Pharmaceutical Co., Ltd. Before that, he served as the financial director, marketing director and general manager of Famacia Puqiang Company in China, and since 2004, he has served as an independent director of the voice. 20 12 10, Liu Hongquan became the CEO and executive director of the board of directors of the voice group.
Zhou Jindong
Zhou Jindong, executive vice president of voice; 1982 graduated from Nanjing University of Traditional Chinese Medicine, majoring in traditional Chinese medicine. 1996 Up to now, he has served as general manager of Nanjing simcere, deputy general manager of Jiangsu simcere, general manager of Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd. and general manager of (Hainan) simcere. In 2008, he obtained a master's degree in economics from Macquarie University in Australia.
Tianjialun
Tian Jialun, Executive Vice President of Voice; 1989 Graduated from Jiangsu Radio and TV University, majoring in accounting; In 2002, she passed the MBA course in Tsinghua University and obtained the certificate of completion. In 2008, he obtained a master's degree in business administration from Hong Kong Baptist University; 1984 to 2000, successively served as the manager of the finance department of Nanjing Guohai Bioengineering Co., Ltd., the deputy director of Nanjing Liuhe Pharmaceutical Factory and the manager of the finance department of Nanjing Chang 'ao Pharmaceutical Co., Ltd. ... He joined Xiansheng in 2000. From 2000 to 2008, he successively served as assistant to the general manager's office, regional manager of the Ministry of Commerce, commercial director of the Ministry of Commerce, general manager of the Ministry of Commerce, deputy general manager of Jiangsu Xiansheng, general manager of the purchasing department of the Group, general manager of Guangdong Guiqiong Branch, assistant to the president of the Group and vice president of the Group.
Yin Xiaojin
Yin Xiaojin, senior vice president of voice, professor-level senior engineer and licensed pharmacist; 1982 obtained a bachelor's degree in pharmacy from China Pharmaceutical University; General Manager of Pharmaceutical Factory of China Pharmaceutical University from 199 1 to1992; 1992-2000 Director of Pharmaceutical Research Department of China Pharmaceutical University; From 2000 to 2003, he served as assistant general manager of Jiangsu simcere Co., Ltd. and general manager of new drug research center; 200 1 Master's degree in industrial engineering from Nanjing University of Science and Technology; Since 2003, he has served as the general manager of Jiangsu Xiansheng Pharmaceutical Research Co., Ltd. ..
Qian Haibo
Qian Haibo, secretary of the board of directors, senior economist and licensed pharmacist; 1984 Graduated from Department of Stomatology, Nanjing Medical University; 1986, Bachelor of Laws, Nanjing Normal University; 1993 obtained a master's degree in health economics from Shanghai Medical University; 1986~ 1993, Director of Health Economics Research Office of Nanjing Medical University; 65438-0993 joined simcere, and served as director, special assistant to CEO, general manager of market strategy department and general manager of department; In 2002, he received a master's degree in business administration from Nanjing University. In 2005, he became the special assistant to the CEO of Shanghai Fosun Pharma Company. In 2007, he received a doctorate in management and social pharmacy from China Pharmaceutical University.
Feng quanfu
Feng Quanfu, Vice President of Voice, Bachelor of Education from East China Normal University, Master of Medicine from Nanjing University of Chinese Medicine, Adjunct Professor from Nanjing University of Chinese Medicine. 1995 joined simcere, and has working experience in corporate culture department, marketing and advertising department, general manager's office, human resources department, commerce department, hospital department and other departments. He has served as the manager of Jiangsu Xiansheng Zhejiang, Fujian and Jiangxi regions, the manager of Suzhou and Shanghai regions in South China, the manager of Guangdong branch, the manager of Beijing branch, the director of the dean's office, the assistant dean and the general manager of the First Hospital, the general manager of the hospital department, the deputy general manager of Jiangsu Xiansheng, and the general manager of North China branch.
Liu Jie
Liu Jie, Vice President of Xiansheng Technology and President of Xiansheng USA Branch, is in charge of the overseas strategic cooperation and business of Xiansheng Technology in the United States. She holds a doctorate in pharmacy from the University of Texas at Austin and an MBA from Columbia University, and has 65,438+02 years of medical experience. Liu Jie joined Xiansheng in 2009. Prior to that, she was the vice president of Allozyne in Seattle, USA. From 2006 to 2008, Liu Jie served as the director of business development and strategic planning of AstraZeneca in China. Prior to this, Liu Jie worked for Boston Consulting Group, providing strategic and operational consulting for Fortune 500 companies. Liu Jie's main offices are located in Seattle, USA and Princeton, New Jersey.